DCTH

#3154
Delcath Systems Inc
10.8800 USD
+4.11%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
10.8800
10.8800
年范围
8.1200
11.1500
日变化
+4.11%
每月变动
+13.45%
6个月变化
+5.22%
年变化
+5.22%
前一天收盘价
10.4500
开盘价
10.8800
买价
卖价
最低价
10.8800
High
10.8800
交易量
45
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 378.0385 M
  • Employee 156
  • Founded 1988
  • CEO Gerard Michel
  • Website www.delcath.com
  • Headquarter Delaware, United States
  • FIGI BBG000BY2VF5
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
144.29
市销率
4.73

Delcath Systems Inc

Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.

新闻